H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $150 from $130 and keeps a Buy rating on the shares after the company reported the interim analysis from the Phase 2b portion of the Phase 2/3 AZURE-1 study, evaluating subcutaneous brelovitug in patients with hepatitis delta virus. The results “provide glimpse at brelovitug’s clean profile,” the analyst tells investors in a research note. H.C. Wainwright believes brelovitug’s clinical profile remains favorable in this randomized setting. It reiterates Mirum as a top pick.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum’s brelovitug succeeds in Phase 2b HDV trial
- Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study
- Mirum Therapeutics: Favorable Risk/Reward Ahead of Key 2Q26 VISTAS Readout for Volixibat in PSC
- Mirum Pharmaceuticals price target raised to $125 from $117 at TD Cowen
- Buy Rating on Mirum Pharmaceuticals Driven by Volixibat’s Differentiated IBAT Profile, Favorable PBC Market Dynamics, and Upside from PSC Expansion